On the contrary, a prospective multicenter study of 58 T2DM patients with stable HF in Japan reported an association between the use of dapagliflozin and a decrease in LAVI and LVMI (both p  <  0.001), but no association with brain natriuretic peptide (BNP) 6 months after the administration of dapagliflozin [15]. The gene discussed is NPPB; the disease is type 2 diabetes mellitus.